High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease.

ABSTRACT:

Background and aim

While weight gain during infliximab therapy in inflammatory bowel disease (IBD) is common, there has been limited research evaluating its impact on infliximab efficacy.

Methods

Primary aims of this study were to determine the frequency of excess weight gain (body mass index [BMI] > 25 kg/m²) in children with IBD on maintenance infliximab and evaluate the impact on infliximab dosing, serum trough levels, and treatment failure. Secondary aims were to determine differences in weight gain, treatment characteristics, and clinical/biochemical variables between patients with therapeutic and subtherapeutic maintenance therapy trough levels. We performed a retrospective study of 253 pediatric IBD (75.1% Crohn's disease, 23.3% ulcerative colitis, 1.6% IBD

SUBMITTER: Rodin I 

PROVIDER: S-EPMC7273726 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature